Sungjin Kim, CEO of MedPacto, Delivers Keynote Speech at Global Bio Conference

Sungjin Kim, CEO of MedPacto

[Asia Economy Reporter Eunmo Koo] MedPacto announced that CEO Sungjin Kim delivered a keynote speech on the theme of "K-Bio Ventures: Directions and Future" at the Global Bio Conference 2020 (GBC2020) held on the 7th.

GBC2020 is an event hosted annually by the Ministry of Food and Drug Safety to review global biopharmaceutical development trends and promote international regulatory harmonization. This year's event was held online and attended by pharmaceutical and bio industry stakeholders from 18 countries.

This year, prominent leaders driving the global pharmaceutical market participated as speakers, including Julie Gerberding, Senior Vice President of MSD; Joerg Michael Rupp, Global Head of Roche; Robert Joseph Smith, Senior Vice President of Pfizer’s Global Rare Disease Business Unit; and Liz Henderson, Head of Merck APAC Healthcare.

In his keynote speech, CEO Kim stated, "The future economic development of South Korea will be led by the pharmaceutical and bio sectors, especially in areas such as rare diseases, diabetes-related conditions, diagnostics, and advanced bio industries utilizing artificial intelligence (AI) technology."

He added, "Global pharmaceutical companies are already accelerating convergence by partnering with or acquiring IT companies to evolve into advanced bio enterprises. With AI technology applied to various fields such as mechanism research, new drug candidate discovery, and clinical trials, the technological gap will widen further."

CEO Kim also emphasized that for K-Bio to gain competitiveness in the global market, urgent efforts are needed including ▲national-level attention and technological development across all pharmaceutical and bio industry sectors ▲training of bio-specialized talent for innovative drug development.

This year's GBC2020 is being held online from the 7th to the 9th.

This content was produced with the assistance of AI translation services.